BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ben Venue Laboratories Resumes Limited Production at Troubled Ohio Plant


10/18/2012 7:54:37 AM

Boehringer Ingelheim GmbH'sBen Venue Laboratories unit has resumed limited drug manufacturing at its troubled Ohio plant, as it continues to fix the facility. Ben Venue, a contract manufacturer, had suspended production at its Bedford, Ohio, site in November 2011 after health authorities identified manufacturing deficiencies, including contamination problems. The company said in a statement Tuesday it resumed manufacturing on a limited number of lines at the plant, and expects to add manufacturing lines as it makes progress upgrading its plant. For most products, supplies won't be available for at least several months, the company said. Ben Venue's troubles caused a shortage of Johnson & Johnson's (JNJ) cancer drug Doxil, as well as supply disruptions and recalls for other products it made on behalf of other drug companies. J&J said earlier this week it would restore full access to Doxil by releasing the remaining reserve made before Ben Venue's shutdown, and shifting to newly manufactured supply that J&J expects in the near future. The new supply is expected to be produced by Ben Venue in available areas of its Bedford plant, while another supplier will handle sterilization-related tasks for the injectable drug.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->